Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Zhen Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4502-0801; OpenAlex author ID A5100457690. Sources: OpenAlex.

Their work

Papers
70 (first author 3, last author 28)
Trials
0
Grants
0
Labs led
2
Collaborators
109
Papers, trials and grants by year

2011: 4 papers · 2012: 3 papers · 2013: 6 papers · 2014: 4 papers · 2015: 4 papers · 2016: 4 papers · 2017: 3 papers · 2018: 9 papers · 2019: 9 papers · 2020: 6 papers · 2021: 5 papers · 2022: 4 papers · 2023: 2 papers · 2024: 3 papers · 2025: 2 papers · 2026: 2 papers

Papers 50 of 70

  1. Harnessing Tumor-Specific Transcript Diversity Uncovers a Shared Neoantigen Reservoir for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/mco2.70890↗
  2. Luteolin Triggers Pyroptosis in Pancreatic Ductal Adenocarcinoma by Inhibiting Mitochondrial Fission through the RAS/ERK/DRP1 Pathway. Last author DOI 10.1142/s0192415x26500606↗
  3. Modified Sijunzi Decoction Inhibits Pancreatic Cancer Progression and Improves Immune Suppression: Network Pharmacology and Experimental Validation. Last author DOI 10.2147/dddt.s520390↗
  4. Identification of Syndrome Types in Patients With Pancreatic Cancer From Free Text in Electronic Medical Records: Model Development and Validation. Last author DOI 10.2196/70602↗
  5. KIF20B and MET, hub genes of DIAPHs, predict poor prognosis and promote pancreatic cancer progression. Last author DOI 10.1016/j.prp.2023.155046↗
  6. Digital subtraction angiography-guided pancreatic arterial infusion of GEMOX chemotherapy in advanced pancreatic adenocarcinoma: a phase II, open-label, random… Co-author DOI 10.1186/s12885-024-12695-8↗
  7. EIF2Ss, a Novel c-Myc-Correlated Gene Family, is Associated with Poor Prognosis and Immune Infiltration in Pancreatic Adenocarcinoma. Last author DOI 10.31083/j.fbl2903119↗
  8. Paired protein kinases PRKCI-RIPK2 promote pancreatic cancer growth and metastasis via enhancing NF-κB/JNK/ERK phosphorylation. Last author DOI 10.1186/s10020-023-00648-z↗
  9. Mechanistic Insights into the Roles of the IL-17/IL-17R Families in Pancreatic Cancer. Co-author DOI 10.3390/ijms241713539↗
  10. Matrine injection inhibits pancreatic cancer growth via modulating carbonic anhydrases- a network pharmacology-based study with in vitro validation. Co-author DOI 10.1016/j.jep.2021.114691↗
  11. Comprehensive analysis of expression profile and prognostic significance of interferon regulatory factors in pancreatic cancer. Last author DOI 10.1186/s12863-021-01019-5↗
  12. Comprehensive analysis of prognostic value and immune infiltration of CXC chemokines in pancreatic cancer. Last author DOI 10.1186/s12920-022-01246-4↗
  13. Fibroblast activation protein-based theranostics in pancreatic cancer. Last author DOI 10.3389/fonc.2022.969731↗
  14. Functional inhibition of lactate dehydrogenase suppresses pancreatic adenocarcinoma progression. Co-author DOI 10.1002/ctm2.467↗
  15. A Notch-Dependent Inflammatory Feedback Circuit between Macrophages and Cancer Cells Regulates Pancreatic Cancer Metastasis. Co-author DOI 10.1158/0008-5472.can-20-0256↗
  16. Kaempferol induces ROS-dependent apoptosis in pancreatic cancer cells via TGM2-mediated Akt/mTOR signaling. Last author DOI 10.1186/s12885-021-08158-z↗
  17. HELLS serves as a poor prognostic biomarker and its downregulation reserves the malignant phenotype in pancreatic cancer. Last author DOI 10.1186/s12920-021-01043-5↗
  18. CMTM8 as an LPA1-associated partner mediates lysophosphatidic acid-induced pancreatic cancer metastasis. Co-author DOI 10.21037/atm-20-1013↗
  19. Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for the detection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/gutjnl-2019-318860↗
  20. Albumin-to-alkaline phosphatase ratio serves as a prognostic indicator in unresectable pancreatic ductal adenocarcinoma: a propensity score matching analysis. Last author DOI 10.1186/s12885-020-07023-9↗
  21. CXCL9 chemokine promotes the progression of human pancreatic adenocarcinoma through STAT3-dependent cytotoxic T lymphocyte suppression. Co-author DOI 10.18632/aging.102638↗
  22. Albumin-to-alkaline phosphatase ratio serves as a prognostic indicator in unresectable pancreatic ductal adenocarcinoma: a propensity score matching analysis Last author DOI 10.21203/rs.2.24244/v1↗
  23. Paeonol Inhibits Pancreatic Cancer Cell Migration and Invasion Through the Inhibition of TGF-β1/Smad Signaling and Epithelial-Mesenchymal-Transition. Last author DOI 10.2147/cmar.s224416↗
  24. Serum level of CCL2 predicts outcome of patients with pancreatic cancer. Co-author PMID 32603049↗
  25. Functions and clinical implications of exosomes in pancreatic cancer. Co-author DOI 10.1016/j.bbcan.2018.11.001↗
  26. Overexpressed N-fucosylation on the cell surface driven by FUT3, 5, and 6 promotes cell motilities in metastatic pancreatic cancer cell lines. Last author DOI 10.1016/j.bbrc.2019.02.092↗
  27. A novel scoring system based on hemostatic parameters predicts the prognosis of patients with advanced pancreatic cancer. Co-author DOI 10.1016/j.pan.2018.12.010↗
  28. Plasma IFN-γ-inducible chemokines CXCL9 and CXCL10 correlate with survival and chemotherapeutic efficacy in advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2019.01.015↗
  29. Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer. Co-author DOI 10.1186/s12967-019-1782-x↗
  30. Long non-coding RNA LINC00346 promotes pancreatic cancer growth and gemcitabine resistance by sponging miR-188-3p to derepress BRD4 expression. Co-author DOI 10.1186/s13046-019-1055-9↗
  31. Do Patients Diagnosed with Metastatic Pancreatic Cancer Benefit from Primary Tumor Surgery? A Propensity-Adjusted, Population-Based Surveillance, Epidemiology … Last author DOI 10.12659/msm.917106↗
  32. Magnesium transporter protein solute carrier family 41 member 1 suppresses human pancreatic ductal adenocarcinoma through magnesium-dependent Akt/mTOR inhibiti… Co-author DOI 10.18632/aging.101940↗
  33. Long non-coding SBF2-AS1 acting as a competing endogenous RNA to sponge microRNA-142-3p to participate in gemcitabine resistance in pancreatic cancer via upreg… Co-author DOI 10.18632/aging.102307↗
  34. Pretreatment values of bilirubin and albumin are not prognostic predictors in patients with advanced pancreatic cancer. Co-author DOI 10.1002/cam4.1848↗
  35. CBX3 promotes proliferation and regulates glycolysis via suppressing FBP1 in pancreatic cancer. Last author DOI 10.1016/j.bbrc.2018.04.137↗
  36. Natural Compound Methyl Protodioscin Suppresses Proliferation and Inhibits Glycolysis in Pancreatic Cancer. Last author DOI 10.1155/2018/7343090↗
  37. Serum levels of IL-6, IL-8, and IL-10 are indicators of prognosis in pancreatic cancer. Co-author DOI 10.1177/0300060518800588↗
  38. TAM Infiltration Differences in "Tumor-First" and " ZHENG-First" Models and the Underlying Inflammatory Molecular Mechanism in Pancreatic Cancer. Last author DOI 10.1177/1534735418771193↗
  39. Benefit from the inclusion of surgery in the treatment of patients with stage III pancreatic cancer: a propensity-adjusted, population-based SEER analysis. Last author DOI 10.2147/cmar.s167103↗
  40. LncRNA AB209630 inhibits gemcitabine resistance cell proliferation by regulating PI3K/AKT signaling in pancreatic ductal adenocarcinoma. Co-author DOI 10.3233/cbm-181182↗
  41. Overexpression of CBX3 in Pancreatic Adenocarcinoma Promotes Cell Cycle Transition-Associated Tumor Progression. Last author DOI 10.3390/ijms19061768↗
  42. Knockdown of FUT3 disrupts the proliferation, migration, tumorigenesis and TGF-β induced EMT in pancreatic cancer cells. Last author DOI 10.3892/ol.2018.8738↗
  43. Radiofrequency ablation for hepatic oligometastatic pancreatic cancer: An analysis of safety and efficacy. Co-author DOI 10.1016/j.pan.2017.08.072↗
  44. Serum lactate dehydrogenase predicts prognosis and correlates with systemic inflammatory response in patients with advanced pancreatic cancer after gemcitabine… Last author DOI 10.1038/srep45194↗
  45. Low serum miR-373 predicts poor prognosis in patients with pancreatic cancer. Co-author DOI 10.3233/cbm-170231↗
  46. A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Last author DOI 10.1002/cncr.30057↗
  47. Cyr61-positive cancer stem-like cells enhances distal metastases of pancreatic cancer. Co-author DOI 10.18632/oncotarget.12248↗
  48. Is chronic hepatitis B infection a protective factor for the progression of advanced pancreatic ductal adenocarcinoma? An analysis from a large multicenter coh… Co-author DOI 10.18632/oncotarget.13000↗
  49. ROR functions as a ceRNA to regulate Nanog expression by sponging miR-145 and predicts poor prognosis in pancreatic cancer. Co-author DOI 10.18632/oncotarget.6450↗
  50. Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells. Co-author DOI 10.1007/s13277-015-3097-8↗

Closest collaborators

The 25 strongest of 109 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chien‐shan Cheng · 18 shared papers, 2018–2025 · strength 2.78
  2. Zhiqiang Meng · 35 shared papers, 2011–2021 · strength 2.53
  3. Lianyu Chen · 25 shared papers, 2011–2022 · strength 2.39
  4. Linjie Ruan · 6 shared papers, 2023–2026 · strength 1.54
  5. Peng Wang · 22 shared papers, 2011–2021 · strength 1.50
  6. Yongqiang Hua · 11 shared papers, 2014–2024 · strength 1.03
  7. Peiwen Yang · 4 shared papers, 2022–2026 · strength 1.01
  8. Fengjiao Wang · 5 shared papers, 2021–2024 · strength 1.00
  9. Juying Jiao · 5 shared papers, 2021–2024 · strength 1.00
  10. Yanhua Jing · 5 shared papers, 2020–2024 · strength 0.94
  11. Hao Chen · 12 shared papers, 2014–2020 · strength 0.90
  12. Yuan Zhang · 3 shared papers, 2025–2026 · strength 0.89
  13. He Ba · 3 shared papers, 2025–2026 · strength 0.89
  14. Yawen Geng · 9 shared papers, 2015–2021 · strength 0.77
  15. Ke Zhang · 4 shared papers, 2019–2024 · strength 0.75
  16. Luming Liu · 10 shared papers, 2013–2019 · strength 0.68
  17. Hao Chen · 6 shared papers, 2014–2024 · strength 0.64
  18. Zhangqi Cao · 3 shared papers, 2021–2024 · strength 0.59
  19. Waimei Si · 2 shared papers, 2025–2026 · strength 0.58
  20. Xin Li · 2 shared papers, 2025–2026 · strength 0.58
  21. Qi Qi · 8 shared papers, 2014–2020 · strength 0.57
  22. Huifeng Gao · 6 shared papers, 2013–2022 · strength 0.55
  23. Lanyun Feng · 5 shared papers, 2016–2024 · strength 0.55
  24. Chao Qu · 6 shared papers, 2014–2021 · strength 0.54
  25. Luming Liu · 11 shared papers, 2011–2019 · strength 0.54

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.